Clinical Outcomes of Neuroendocrine Prostate Cancer Treated With Platinum-Based Chemotherapy: A Single-Institution Experience.
INTRODUCTION Neuroendocrine prostate cancer (NEPC) is aggressive with a poor prognosis. Most reported series derive from large databases (e.g., SEER) lacking granular clinical detail. We examined our institution's experience with 58 patients with NEPC. PATIENTS We identified patients with biopsy-proven NEPC treated w...